Breaking News

Synergy Completes Callisto Merger

January 18, 2013

Gains cancer therapeutics expertise

Synergy Pharmaceuticals, a drug developer focused on gastrointestinal disorders and diseases, has concluded its merger with Callisto Pharmaceuticals, a biotechnology company that develops novel therapeutics to treat cancer.
Under the terms of the merger agreement, each outstanding share of Callisto common stock was converted into one share of Synergy common stock and the approximately 22.3 million shares of Synergy held by Callisto were canceled. Callisto's common stock will no longer be traded on the OTC QB.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks